| Table 1. | Definitions of Some Terms Used in These Guidelines |
| Table 2. | Stages of Chronic Kidney Disease |
| Table 3. | Dyslipidemias as Defined in the Adult Treatment Panel III Guidelines |
| Table 4. | Some Government-Sponsored Web Sites With Information Useful in Risk Factor Management |
| Table 5. | Key Features of the NKF-KDOQI Guidelines That Differ From Those of the National Cholesterol Education Program Adult Treatment Panel III |
| Table 6. | Key Features of the NKF-KDOQI Guidelines That Differ From Those of the National Cholesterol Expert Panel on Children |
| Table 7. | Rating the Strength of Recommendations |
| Table 8. | Rating the Strength of Evidence |
| Table 9. | Exclusion of CKD Patients in Some Recent, Large, Pivotal, Lipid-Lowering Trials |
| Table 10. | Associations Between Dyslipidemias and Cardiovascular Disease in Hemodialysis Patients |
| Table 11. | Associations Between Dyslipidemias and Cardiovascular Disease in Peritoneal Dialysis Patients |
| Table 12. | Associations Between Dyslipidemias and Cardiovascular Disease in Kidney Transplant Recipients |
| Table 13. | Relationship Between Dyslipidemias and Kidney Disease Progression |
| Table 14. | The Prevalence of Dyslipidemias in Adults |
| Table 15. | The Prevalence of Dyslipidemias in Children and Adolescents |
| Table 16. | Prevalence of Dyslipidemias Among 1,047 Hemodialysis Patients |
| Table 17. | Prevalence of Dyslipidemias Among 317 Peritoneal Dialysis Patients |
| Table 18. | Serum Total Cholesterol Levels in U.S. Children and Adolescents |
| Table 19. | Serum LDL Levels in U.S. Children and Adolescents |
| Table 20. | Serum HDL Levels in U.S. Children and Adolescents |
| Table 21. | Serum Triglycerides in U.S. Children and Adolescents |
| Table 22. | Transient Effects of Some Acute Conditions on Lipid Levels |
| Table 23. | Randomized Trials Evaluating the Effects of Immunosuppressive Agents on Dyslipidemias After Kidney Transplantation |
| Table 24. | Secondary Causes of Dyslipidemias |
| Table 25. | The Management of Dyslipidemias in Adults With Chronic Kidney Disease |
| Table 26. | Therapeutic Lifestyle Changes (TLC) for Adults With Chronic Kidney Disease |
| Table 27. | Randomized Trials Evaluating the Treatment of Dyslipidemias in Hemodialysis Patients |
| Table 28. | Randomized Trials Evaluating the Treatment of Dyslipidemias in Peritoneal Dialysis Patients |
| Table 29. | Randomized Trials Evaluating the Treatment of Dyslipidemia in Kidney Transplant Recipients |
| Table 30. | Lipid-Lowering Medication Dose Adjustments for Reduced Kidney Function |
| Table 31. | Recommended Daily Statin Dose Ranges |
| Table 32. | Effects of Cyclosporine on Blood Levels of Statins in Kidney Transplant Recipients |
| Table 33. | Effects of the Macrolide Antibiotic Erythromycin on Blood Levels of Statins in Normal Individuals |
| Table 34. | Effects of Azole Antifungal Agents on Blood Levels of Statins in Normal Individuals |
| Table 35. | Effects of Calcium-Channel Blockers on Blood Levels of Statins in Normal Individuals |
| Table 36. | Agents That May Alter Statin Blood Levels |
| Table 37. | The Effects of Fibrates on Blood Levels of Statins in Normal Individuals |
| Table 38. | Bile Acid Sequestrant Dose |
| Table 39. | Relative Effect of Different Immunosuppressive Agents on Cardiovascular Disease Risk Factors After Kidney Transplantation |
| Table 40. | Maximum Doses of Fibrates in Patients With Reduced Kidney Function |
| Table 41. | Nicotinic Acid Dose |
| Table 42. | Intervention Trials That Are Needed in Patients With Chronic Kidney Disease |
| Table 43. | Example of Format for Evidence Tables for Cardiovascular Risk |
| Table 44. | Example of Format for Evidence Tables for Treatment Effect |
| Table 45. | Format for Guidelines |
| Table 46. | Dietary Modifications That May Be Appropriate for Adults With Chronic Kidney Disease |
| Table 47. | Nutritional Characteristics of Some Protein-Source Food Items |
| Table 48. | Margarines Containing Plant Sterol/Stanol Esters |
| Table 49. | Contents of Some Commercially Available Cereals High in Fiber |
| Table 50. | Contents of Some Fruits High in Fiber |
| Table 51. | Contents of Some Vegetables High in Fiber |
| Table 52. | Contents of Some Breads High in Fiber |
| Table 53. | The Electrolyte Content of Some Commonly Used Fiber Supplements |